Liquid Formulations for Stabilizing IgMs During Physical Stress and Long-Term Storage
To develop a liquid formulation for IgMs to survive physical stress and storage.
Stabilizing formulations for 8 monoclonal immunoglobulin (IgMs) were found using differential scanning calorimetry (DSC). In these formulations, the IgMs were subjected to stress and storage and analyzed by size exclusion chromatography and fluorescence activated cell sorting. Structure was analyzed using small-angle X-ray scattering (SAXS).
The highest conformational stability was found near the isoelectric point and further enhanced by addition of sorbitol, sucrose and glycine. For 2 IgMs, the pH optimum for conformational and storage stability did not correspond. Lowering the pH led to the desired storage stability. Optimized formulations prevented aggregation and fragmentation from shear stress, freeze-thaw cycles, accelerated storage and real time storage at 4°C and −20°C for 12 months. Optimized formulations also preserved immunoreactivity for 12 months. SAXS indicated that IgM in stabilizing conditions was closer to the structural IgM model (2RCJ) and less susceptible for aggregation.
A long-term stabilizing formulation for 8 IgMs was found comprising 20% sorbitol and 1 M glycine at pH 5.0–5.5 which may have broad utility for other IgMs. Formulation development using DSC and accelerated storage was evaluated in this study and may be used for other proteins.
KEY WORDSconformational stability DSC formulation IgM protein aggregation
- 4.Secher T, Fauconnier L, Szade A, Rutschi O, Fas SC, Ryffel B, et al. Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection. J Antimicrob Chemother. 2011;66(5):1100–9.PubMedCrossRefGoogle Scholar
- 33.Eriksson L, Johansson E, Kettaneh-Wold N, Wikstroem C, Wold S. Design of experiments: principles and applications. Umea, Sweden: Umetrics Academy; 2008.Google Scholar
- 42.Bhambhani A, Kissmann JM, Joshi SB, Volkin DB, Kashi RS, Middaugh CR. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions. J Pharm Sci. 2011;101(3):1120–35.PubMedCrossRefGoogle Scholar
- 46.Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, et al. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci U S A. 1997;94(22):11917–22.PubMedCrossRefGoogle Scholar